Acta Cardiologia Indonesiana (Vol. 3 No. 2) 2017 [supplement]: S6

Pulmonary Hypertention in Indonesia: Where and how is the Data? What is the Gaps?

Bambang Budi Siswanto

Working Group on Heart Failure and Pulmonary Hypertension Indonesia Heart Association www.inahf-ph-carmet.org Department Cardiology and Vascular Medicine Faculty of Universitas Indonesia -National Cardiovascular Center Harapan Kita Jakarta Indonesia Email: bambbs@gmail.com

Geographically Indonesia is the largest archipelago country and the most populated no 4 in the world. After 72 years as indepence country then since 2014 started the National Health Coverage. Despite still many infectious disease, the non communicable and new emerging diseases still found. Indonesia had no exact data about Pulmonary Hypertension because of the lack participation of doctors and hospitals to joinour national registry: www.ina-registry.org.We are facing various obstacles. Some concerns that made Pulmonary Hypertension as Diagnostic and Treatment problem are (1)Poor knowledge about the etiology and pathophysiology of this abnormality. The etiology are varies but undetected congenital heart disease in the childhood then came at late stage (Grown Up Congenital Heart Disease) (2) Lack of Diagnostic and Treatment Facility (Lung V/Q scan, RHC) (3) Limited Drug Coverability on National Health Insurance, (4) Expensive PH Drug Cost are the problems that must be solved to improve PH outcome. However, in the last six years there are significant increases of referall case at PH clinic at our NCVC Jakarta. The need for PH Clinic / center with good fascilities and expert and generic PH medication is important. Early detection of congenital heart disease in neonates and children combined with pediatric surgery is mandatory. We should star the National Registry on PH and make PH clinic in big province hospital.